This study overcomes the limitations of traditional anticancer effects of Ganoderma lucidum and pioneers an innovative cultivation system for anticancer Reishi based on synergistic bio-enhancement integrating “traditional Chinese medicine (TCM) compound formula — enzymatic pretreatment — gene editing — transgenic metabolism.” The core technologies include: Construction of a cultivation substrate incorporating anticancer TCM compound formulas; Application of targeted enzymatic hydrolysis technology to efficiently cleave macromolecular active components in TCM; Precise modification of membrane transport systems in Ganoderma strains using the CRISPR-Cas9 gene-editing platform; Reconstruction of metabolic pathways through transgenic technology to achieve synergistic enrichment and stable storage of exogenous antitumor active components together with endogenous functional components of Ganoderma. Experimental results demonstrate that this innovatively cultivated Ganoderma lucidum can effectively activate the body’s immune defense, inhibit cancer cell proliferation through multiple targets, and induce apoptosis, while exhibiting safety with no toxic side effects. This research provides a disruptive technological pathway and a highly promising candidate carrier for the development of efficient, safe, and cost-effective cancer biotherapeutic agents.
Jin XZ, Ruiz Beguerie J, Sze DM, et al., 2016, Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews, 2016(4): CD007731. https://doi.org/10.1002/14651858.CD007731.pub3.
Lü YJ, Zhou ST, Wang LN, et al., 2024, Research Progress on the Antitumor Mechanisms of Active Components from Ganoderma lucidum. Chinese Journal of Clinical Pharmacology and Therapeutics, 29(8): 947–954. https://doi.org/10.12092/j.issn.1009-2501.2024.08.012
Li RT, Zhang Y, Chen JN, et al., 2022, Co-fermentation of Marsdenia tenacissima with Ganoderma lucidum and Anti-lung Cancer Effect of the Fermentation Products. Journal of Visualized Experiments (JoVE), 2022(188): e64531. https://doi.org/10.3791/64531
He S, Xu XL, Zhang ZG, et al., 2025, Gene Editing of Ganoderma lucidum: Developments, Challenges, and Future Perspectives. Mycology Journal, 11(4): 310. https://doi.org/10.3390/jof11040310
Tan Y, Yu XL, Zhang ZG, et al., 2023, An Efficient CRISPR/Cas9 Genome Editing System for a Ganoderma lucidum Cultivated Strain by Ribonucleoprotein Method. Proceedings of the 2023 Annual Academic Conference of the Mycological Society of China. Journal of Fungi, 9(12): 1170.
Yuan W, Jiang CJ, Wang Q, et al., 2022, Biosynthesis of Mushroom-derived Type II Ganoderic Acids by Engineered Yeast. Nature Communications, 13(1): 1–15. https://doi.org/10.1038/s41467-022-35500-1
Zhang X, Liu S, Wu KY, et al., 2025, Structural characterization and Anti-colorectal Cancer Activity of a Fucogalactan Purified from Ganoderma tsugae. Carbohydrate Polymers, 2025(352): 123203. https://doi.org/10.1016/j.carbpol.2024.123203